Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

Papatheofanis F J, McKenzie R S, Mody S H, Suruki R Y, Piech C T

**Record Status**
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

**Bibliographic details**

**Indexing Status**
Subject indexing assigned by NLM

**MeSH**
Anemia, Hemolytic /drug therapy /etiology; Disease Progression; Dose-Response Relationship, Drug; Drug Costs /statistics & numerical data; Epoetin Alfa /administration & dosage /economics; Erythropoietin /administration & dosage /analogs & derivatives /economics; Female; Hematinics /administration & dosage /economics; Hemoglobins /drug effects; Humans; Kidney Failure, Chronic /blood /complications; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Time Factors; Treatment Outcome

**AccessionNumber**
22006001182

**Date bibliographic record published**
06/07/2006